Clinical trials: sponsored by CSL Behring
Inflammation, Frailty
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study
The goal of this clinical trial is to learn about the effects of inflammation-lowering therapy on mobility and disability in older adults.
- Trial name
- RIGHT (NCT05727384)
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Anne B. Newman
Common Variable Immunodeficiency
Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease
Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published study to guide immunologists…
- Trial name
- NCT05193552
- Testing
- Hizentra
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Liver Cirrhosis
Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis
Haemostasis of cirrhotic patients is disturbed at different levels: primary haemostasis, coagulation and fibrinolysis, leading to a new haemostatic balance.
- Trial name
- HEMCITAP (NCT06050993)
- Testing
- Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Complement-mediated Disorders
First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects
First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects
- Trial name
- NCT05937581
- Testing
- CSL040
- Where
- Australia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy Volunteers
Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults
This is a phase I, single-center, randomized, open-label, single-dose, 2-way, 2-period, crossover study to evaluate the effect of food on the pharmacokinetics (PK) of vamifeport prolonged-release (PR) formulation in healthy adult…
- Trial name
- NCT06996184
- Testing
- Vamifeport (PR formulation)
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy Volunteers
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults
This is a phase 1, single-center, randomized, open-label study to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of vamifeport after multiple oral administrations of one immediate-release (IR)…
- Trial name
- NCT06726863
- Testing
- Vamifeport IRF, Vamifeport PR1, Vamifeport PR2
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Immune Deficiency
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.
- Trial name
- NCT03968211
- Testing
- Salmonella typhi polysaccharide vaccine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Asthma
A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers
This is a phase 1, first-in-human (FIH), multi-center, randomized, double-blind, placebo-controlled study of CSL311 in patients with mild-to-moderate asthma.
- Trial name
- NCT04082754
- Testing
- Human beta common receptor antagonist monoclonal antibody
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Noncystic Fibrosis Bronchiectasis (NCFB)
Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after…
- Trial name
- NCT04643587
- Testing
- CSL787
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Immune Complex-mediated Autoimmune Diseases
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
This phase 1, randomized, double-blind, placebo-controlled study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of CSL730 administered by subcutaneous (SC)…
- Trial name
- NCT04446000
- Testing
- CSL730
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy Volunteers
Effects of CSL324 in the Lung After Segmental Challenge
This is a phase 1b, randomized, double-blind, placebo-controlled study in healthy volunteers to investigate the antiinflammatory effect of pretreatment with CSL324 on response to a lipopolysaccharide (LPS) endotoxin challenge in…
- Trial name
- NCT05653713
- Testing
- CSL324
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Clinical Safety of a PBM Program
The German Patient Blood Management Network
This epidemiological trial will determine whether the implementation of a PBM program is safe and effective in terms of clinical outcome compared to a pre-implementation cohort Primary endpoint is a composite outcome comprising…
- Trial name
- NCT02147795
- Where
- 2 sites in Germany
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital
Healthy Participants
A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects
This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe…
- Trial name
- NCT05306275
- Testing
- CSL312
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy
Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Study CSL324_1003 is a single center, randomized, double-blind, placebo-controlled study designed to characterize and compare the PK properties and safety of a single subcutaneous dose of CSL324 in healthy Japanese and White…
- Trial name
- NCT04570267
- Testing
- CSL324
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy Volunteers
A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults
This will be a 2- part, phase 1, open-label, single center, single ascending dose study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of subcutaneous (SC) and intravenous (IV)…
- Trial name
- NCT04580654
- Testing
- CSL312
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Bleeding, Blood Loss, Surgical
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
This will be the first prospective randomized controlled clinical trial directly comparing Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for post cardiopulmonary bypass microvascular bleeding and…
- Conditions
- Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates
- Trial name
- NCT02557672
- Testing
- Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP)
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Coronavirus Disease 2019 (COVID-19)
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
CSL760 is a human hyperimmune product of the purified gamma immunoglobulin (IgG) fraction of human plasma containing polyvalent neutralizing antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
- Trial name
- NCT04638634
- Testing
- CSL760
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CSL Behring
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
Healthy
Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults
To assess the safety and tolerability of ascending doses of CSL730 after a single intravenous (IV) infusion in healthy Caucasian and Japanese subjects
- Trial name
- NCT03375606
- Testing
- CSL730
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Ataxia Telangiectasia, Infections
Susceptibility to Infections in Ataxia Telangiectasia
Death in Ataxia telangiectasia (A-T) is usually due to cancer or chronic lung failure around 20 years of age. Despite low lymphocyte counts (CD3, CD4, CD8 and CD19), IgA and IgG subclass deficiency opportunistic and acute severe…
- Conditions
- Ataxia Telangiectasia, Infections, Immunodeficiency, Lung Disease
- Trial name
- NCT02345135
- Testing
- Blood collection, Lung function measurement, Symptom diary
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital